Table 2.
Distribution of Characteristics in Participants With and Without Hypercholesterolemia Treatment, Diabetes Mellitus, and Metabolic Syndrome
| Characteristic | HA (μg/l) | P‐value | hs‐CRP (mg/dl) | P‐value | Framingham risk score (Low/Intermediate) | P‐value |
|---|---|---|---|---|---|---|
| Dyslipidemia | ||||||
| Yes (n = 142) | 68.8 (3.2) | 0.05 | 0.15 (0.02–1.27) | 0.04 | 118/24 | 0.377 |
| No (n = 58) | 57.5 (3.8) | 0.10 (0.02–1.22) | 50/8 | |||
| Hypercholesterolemia treatment | ||||||
| Yes (n = 119) | 70.0 (3.8) | 0.04 | 0.15 (0.02–1.27) | 0.05 | 100/18 | 0.438 |
| No (n = 81) | 59.1 (3.1) | 0.11 (0.02–1.22) | 68/14 | |||
| Diabetic mellitus | ||||||
| Yes (n = 19) | 90.9 (10.7) | 0.02 | 0.12 (0.03–1.19) | 0.442 | 12/7 | 0.017 |
| No (n = 181) | 62.8 (2.5) | 0.13 (0.02–1.27) | 156/25 | |||
| Metabolic syndrome | ||||||
| Yes (n = 27) | 85.2 (9.7) | 0.03 | 0.2 (0.04–1.19) | 0.001 | 24/3 | 0.001 |
| No (n = 173) | 62.4 (2.5) | 0.1 (0.02–1.27) | 120/53 | |||
For categorical: n (% of participants); for continuous: mean (SEM), except for BMI, hsCRP, which are expressed as median (range).
P‐values were derived from t‐test for HA, Kruskal–Wallis test for hsCRP, and chi‐square test for Framingham risk score.